SLC6A3 and Atrophy: Our choice was based on the lack of absolute consensus on all the available methods, as PVE correction might introduce random noise and unpredictably alter regional SBR (Kanel et al., 2023), and also considering that our target cohort including early-stage disease and healthy controls that have presumably limited atrophy and that the used radiotracer is characterized by high affinity and specificity for DAT.